Lyle Feinstein
Fred Hutchinson Cancer Research Center
11 Papers
173 Citations
Lyle Feinstein is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Transplantation & Total body irradiation. The author has an hindex of 8, co-authored 9 publications. Previous affiliations of Lyle Feinstein include University of Washington.
Chat about Author
Papers
Nonmyeloablative Hematopoietic Cell Transplantation
Lyle Feinstein,Lyle Feinstein,Brenda M. Sandmaier,Brenda M. Sandmaier,David G. Maloney,David G. Maloney,Peter A. McSweeney,Michael B. Maris,Michael B. Maris,Christopher R. Flowers,Christopher R. Flowers,Jerry P. Radich,Jerry P. Radich,Marie Térèse Little,Richard A. Nash,Richard A. Nash,Thomas R. Chauncey,Thomas R. Chauncey,Thomas R. Chauncey,A. Woolfrey,A. Woolfrey,George E. Georges,George E. Georges,Hans-Peter Kiem,Hans-Peter Kiem,Jan M. Zaucha,Karl G. Blume,Judith A. Shizuru,Dietger Niederwieser,Rainer Storb,Rainer Storb +30 more
TL;DR: A minimally myelosuppressive regimen that relies on immunosuppression for allogeneic engraftment was developed to reduce toxicities while optimizing GVT effects, and if long‐term efficacy is demonstrated, such a strategy would expand treatment options for patients who would otherwise be excluded from conventional allografting.
89
Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts.
Lyle Feinstein,Kristy Seidel,Jane Jocum,Raleigh A. Bowden,Claudio Anasetti,H. Joachim Deeg,Mary E.D. Flowers,Emin Kansu,Paul J. Martin,Richard A. Nash,Jan Storek,Ruth Etzioni,Frederick R. Applebaum,John A. Hansen,Rainer Storb,Keith M. Sullivan +15 more
TL;DR: It is concluded that pretransplant loading and a shorter course and lower total dose of IVIg prophylaxis did not appear to decrease the risk of acute GVHD or mortality among adults receiving related donor marrow transplants.
33
Nonmyeloablative hematopoietic cell transplantation.
Lyle Feinstein,Rainer Storb +1 more
TL;DR: The myeloablative doses of chemotherapy and radiation used with conventional allogeneic hematopoietic cell transplantation produce considerable morbidity and mortality that generally limit this treatment to patients younger than 55 years of age and in good general medical condition.
33
Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant.
Lyle Feinstein,Lyle Feinstein,Brenda M. Sandmaier,Brenda M. Sandmaier,David G. Maloney,David G. Maloney,Michael B. Maris,Michael B. Maris,Ted Gooley,Ted Gooley,Thomas R. Chauncey,Thomas R. Chauncey,U Hegenbart,Peter A. McSweeney,Monic J. Stuart,Stephen J. Forman,Edward Agura,Michael A. Pulsipher,Karl G. Blume,Dietger Niederwieser,Rainer Storb,Rainer Storb +21 more
TL;DR: Although the length of follow-up is still short, it appears that encouraging outcomes can be achieved with nonmyeloablative conditioning in patients expected to have poor outcomes with conventional allografting.
31
Type of post-grafting immunosuppression after non-myeloablative blood cell transplantation may influence risk of delayed haemolysis due to minor ABO incompatibility.
Marco Mielcarek,J. Maciej Zaucha,Brenda M. Sandmaier,David G. Maloney,James E. Butrynski,Michael B. Maris,Lyle Feinstein,Beverly Torok-Storb,Rainer Storb +8 more
TL;DR: Non-myeloablative haematopoietic cell transplantation is a relatively novel treatment approach that consists of preparative regimens and post-grafting immunosuppression aimed at preventing graft rejection and clinically intolerable graftversus-host disease while relying on graft-versu-tumour effects for disease eradication.
15